View source for Next-Generation CAR T-Cell Therapy for GBM

{{TreatmentInfo
|drug_name=Next-Generation CAR T-Cell Therapy for GBM
|FDA_approval=In trial phase for GBM; FDA-approved for other cancers
|used_for=Recurrent Glioblastoma Multiforme (GBM)
|clinical_trial_phase=Phase 1 (INCIPIENT trial among others)
|common_side_effects=Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity
|OS_without=Median survival for recurrent GBM typically less than one year
|OS_with=Not fully established; dramatic and rapid tumor regression observed in initial patients
|PFS_without=Not specified
|PFS_with=Significant reduction in tumor size noted, durability of response under investigation
|usefulness_rating=4
|usefulness_explanation=Introduces a novel, highly personalized approach targeting mixed cell populations within GBM tumors. Early results demonstrate potential for substantial impact on tumor reduction and patient outcomes, indicating a promising direction for future GBM treatment strategies.
|toxicity_level=3
|toxicity_explanation=Includes expected side effects such as fevers and altered mental status post-infusion, with significant neurotoxicity that has been manageable in initial patients.
|book_text=Recent advancements in CAR T-cell therapy, particularly the innovative approach taken in the INCIPIENT trial, have shown promising early results for treating GBM. By targeting mixed cell populations within tumors and observing dramatic reductions in tumor size, this therapy represents a potential breakthrough in GBM treatment. While further research is needed to understand long-term effectiveness and manage side effects, these early findings provide hope for more effective GBM therapies.
Ben Williams book: Chimeric antigen receptor (CAR) T-cells are T-cells that have been genetically engineered,
commonly by the use of a retroviral vector, to express artificial receptors specifically
targeted to a chosen tumor-associated or tumor-specific antigen. CAR T-cells directed to
CD19 have been used with impressive success for B-cell acute lymphoblastic leukemia
(ALL), and tisagenlecleucel, an anti-CD19 CAR T-cell therapy was approved for this
indication on August 30, 2017. For glioblastoma, phase 1 CAR T-cell trials are currently
active, with preliminary outcomes now published for two of these trials, as discussed
below.
|links=https://www.massgeneral.org/news/press-release/clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy

}}